| For: | Wu YZ, Wu M, Zheng XH, Wang BZ, Xue LY, Ding SK, Yang L, Ren JS, Tian YT, Xie YB. No long-term survival benefit with sustained-release 5-fluorouracil implants in patients with stages II and III gastric cancer. World J Gastroenterol 2022; 28(38): 5589-5601 [PMID: 36304092 DOI: 10.3748/wjg.v28.i38.5589] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v28/i38/5589.htm |
| Number | Citing Articles |
| 1 |
Jian Sheng, Jianghua Li, Chenxi Cao, Xiaorong Liu, Chunhua He, Mingjian Fei, Bin Wu, Xiangli Li, Chundong Hu, Shumin Liu, Yahui Lv. Targeting RPRD1B overcomes chemoresistance in gastric cancer by suppressing the TOPBP1-mediated DNA damage repair pathway. Cellular Oncology 2026; 49(3) doi: 10.1007/s13402-026-01227-0
|
| 2 |
Gao-shi Huang, Ying Xie, Zhen-yu Jiang, Zhang-qun Xu, Zheng-jia Jin, Ke-chen Xu. Clinical analysis of sustained-release 5-fluorouracil implants during surgery for advanced gastric cancer. Current Problems in Surgery 2025; 66 doi: 10.1016/j.cpsurg.2025.101746
|